

06-06-05

ITW

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>		Application Number	10/823,426
		Filing Date	April 12, 2004
		First Named Inventor	Naweed MUHAMMAD
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	14 pages + 90 refs.	Attorney Docket Number	524522001300


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement - 3 pages <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08a/b + copy - 10 pages Ninety (90) references Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Mika Mayer		
Date	June 2, 2005	Reg. No.	47,777

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 544981345 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: June 2, 2005	Signature: (Jim Yang)

2

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 544981345 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: June 2, 2005 Signature: 

(Jim Ybaol)

Patent

Docket No. 524522001300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Naweed MUHAMMAD et al.

Serial No.: 10/823,426

Filing Date: April 12, 2004

For: METHODS AND COMPOSITIONS FOR
ADMINISTRATION OF TRPV1
AGONISTS



Examiner: Not Yet Assigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.



This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of __ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 524522001300.

Dated: June 2, 2005

Respectfully submitted,

By 

Mika Mayer

Registration No.: 47777

MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-4298



ALTERNATIVE TO PTO/SB08/a/b (06-03)

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/823,426
		Filing Date	April 12, 2004
		First Named Inventor	Naweed MUHAMMAD
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	1	of	5
		Attorney Docket Number	524522001300

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/M.Y.	1.	US-2002/0058048-A1	05-16-2002	Tamura et al.	
	2.	US-2003/0104040-A1	06-05-2003	Kirby et al.	
	3.	US-2003/0104085-A1	06-05-2003	Yeomans	
	4.	US-2005/0084520-A1	04-21-2005	Bernstein	
	5.	US-4,313,958	02-02-1982	LaHann	
	6.	US-4,493,848	01-15-1985	LaHann et al.	
	7.	US-4,532,139	07-30-1985	Janusz et al.	
	8.	US-4,544,668	10-01-1985	Janusz et al.	
	9.	US-4,544,669	10-01-1985	LaHann et al.	
	10.	US-4,564,633	01-14-1986	LaHann et al.	
	11.	US-4,599,342	07-08-1986	LaHann	
	12.	US-4,892,890	01-09-1990	Damani	
	13.	US-5,221,692-A	06-22-1993	Chen	
	14.	US-5,505,958-A	04-09-1996	Bello et al.	
	15.	US-5,654,337-A	08-05-1997	Roentsch et al.	
	16.	US-5,716,643-A	02-10-1998	Yen	
	17.	US-5,762,963-A	06-09-1998	Byas-Smith	
	18.	US-5,879,696-A	03-09-1999	Blumberg	
	19.	US-5,962,532-A	10-05-1999	Campbell et al.	
	20.	US-6,013,270-A	01-11-2000	Hargraves et al.	
	21.	US-6,103,266-A	08-15-2000	Tapolsky et al.	
	22.	US-6,239,180-B1	05-29-2001	Robbins	
	23.	US-6,248,788-B1	06-19-2001	Robbins et al.	
	24.	US-6,264,988-B1	07-24-2001	Yen	
	25.	US-6,299,900-B1	10-09-2001	Reed et al.	
	26.	US-6,390,291-B1	05-21-2002	Garrill et al.	
	27.	US-6,444,234-B1	09-03-2002	Kirby et al.	
/M.Y.	28.	US-6,638,981-B2	10-28-2003	Williams et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² -Number ² -Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/M.Y.	29.	EP-0 225 848-A2	06-16-1987	Warner-Lambert Co.	
	30.	EP-0 347 000-A2	12-20-1989	The Procter & Gamble Co.	
	31.	WO-92/09285-A1	06-11-1992	The Procter & Gamble Company	
	32.	WO-98/03641-A1	01-29-1998	Crandall	
	33.	WO-00/09117-A1	02-24-2000	Edko Trading and Representation Co. Ltd.	
	34.	WO-00/50007-A1	08-31-2000	Lipocine, Inc.	
	35.	WO-00/50387-A1	08-31-2000	Pacific Corporation	
	36.	WO-00/59475-A1	10-12-2000	Lipocine, Inc.	
	37.	WO-00/67730-A1	11-16-2000	U.S. Dermatologics, Inc.	
	38.	WO-2004/021990-A2, A3	03-18-2004	Neurogesx, Inc.	
	39.	WO-2004/091521-A2, A3	10-28-2004	Neurogesx, Inc.	
/M.Y.	40.	WO-2004/092122-A2	10-28-2004	Algor Pharmaceuticals	

Examiner Signature	/Micah Paul Young/ (02/17/2009)	Date Considered	02/17/2009
pa-982742			

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/823,426
		Filing Date	April 12, 2004
		First Named Inventor	Naweed MUHAMMAD
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	2	of	5
		Attorney Docket Number	524522001300

/M.Y.	41.	WO-2005/009510-A2	02-03-2005	The Regents of the University of California	
-------	-----	-------------------	------------	---	--

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. *Error Office that issued the document, by the two-letter code (WPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
/M.Y.	42.	Anonymous (July 2004). "Adding Value with ATD Technology," <i>Antares Pharma AG</i> , pp. 1-38.		
/M.Y.	43.	Anonymous (2004). "I Have Vulvodynia-What Do I Need to Know: A Self-Help Guide for Women Diagnosed with Vulvodynia," <i>National Vulvodynia Association Pamphlet</i> 12 pages.		
/M.Y.	44.	Asbill, C.S. et al. (2000). "Enhancement of Transdermal Drug Delivery: Chemical and Physical Approaches," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 17(6):621-658.		
/M.Y.	45.	Backonja, M.-M. et al. (January 2003). "A Single One Hour Application of High-Concentration Capsaicin Patches Leads to Four Weeks of Pain Relief in Postherpetic Neuralgia Patients," <i>American Academy of Neurology Abstract</i> , two pages.		
	46.	Balaban, C.D. et al. (2003). "Type I Vanilloid Receptor Expression by Mammalian Inner Ear Ganglion Cells," <i>Hear Res.</i> 175:165-170.		
	47.	Barry, B.W. (1993). "Vehicle Effect: What Is An Enhancer?" Chapter 14 In <i>Topical Drug Bioavailability, Bioequivalence, and Penetration</i> Shah, V.P. et al. eds. Plenum Press: New York, NY pp. 261-276.		
	48.	Baudoin, T. et al. (2000). "Capsaicin Significantly Reduces Sinonasal Polyps," <i>Acta Otolaryngol.</i> 120:307-311.		
	49.	Behrendt, H.-J. et al. (2004). "Characterization of the Mouse Cold-Menthol Receptor TRPM8 and Vanilloid Receptor Type-1 VR1 Using a Fluorometric Imaging Plate Reader (FLIPR) Assay," <i>Br. J. Pharmacol.</i> 141:737-745.		
	50.	Belloco, A.M. et al. (1984). "Microemulsions" In <i>Advances in Colloid Interface Science</i> Elsevier Science Publishers B.V., Amsterdam 20:167-272.		
	51.	Berger, A. et al. (April 1995). "Oral Capsaicin Provides Temporary Relief for Oral Mucositis Pain Secondary to Chemotherapy/Radiation Therapy," <i>J. Pain Manage.</i> 10(3):243-248.		
	52.	Bernstein, J.E. et al. (1986). "Effects of Topically Applied Capsaicin on Moderate and Severe Psoriasis Vulgaris," <i>J. Am. Acad. Dermatol.</i> 15:504-507.		
	53.	Bjerring, P. et al. (1989). "Use of a New Argon Laser Technique to Evaluate Changes in Sensory and Pain Thresholds in Human Skin Following Topical Capsaicin Treatment," <i>Skin Pharmacol.</i> 2:162-167.		
	54.	Bley, K.R. (2003). "Advances in Localized Management of Neuropathic Pain," <i>NeurogesX, Inc.</i> pp.1-6.		
	55.	Bourrel, M. et al. (1988). <i>Microemulsions and Related Systems</i> , Marcel Dekker: New York, NY pp. ix-xi (Table of Contents Only).		
	56.	Brand, L.M. et al. (1990). "Anti-Inflammatory Pharmacology and Mechanism of the Orally Active Capsaicin Analogs, NE-19550 and NE-28345," <i>Agents and Actions</i> 31(3/4):329-340.		
	57.	Caterina, M.J. et al. (2001). "The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway," <i>Annu. Rev. Neurosci.</i> 24:487-517.		
/M.Y.	58.	Chancellor, M.B. et al. (July 1999). "Intravesical Capsaicin and Resiniferatoxin Therapy: Spicing up the Ways to Treat the Overactive Bladder," <i>J. Urol.</i> 162:3-11.		

Examiner Signature	/Micah Paul Young/ (02/17/2009)	Date Considered	02/17/2009
pa-982742			

Substitute for form 1449/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/823,426
			Filing Date	April 12, 2004
			First Named Inventor	Naweed MUHAMMAD
			Art Unit	1614
			Examiner Name	Not Yet Assigned
			Attorney Docket Number	524522001300
Sheet	3	of	5	

/M.Y./	59.	Chattaraj, S.C. et al. (1995). "Chemical Penetration Enhancers" Table 1 In "Penetration Enhances Classification" Chapter 1.2 In <u>Percutaneous Penetration Enhancers</u> Smith, E.W. et al. eds. CRC Press: Boca Raton, Florida pp. 7-8.	
/M.Y./	60.	Dray, A. et al. (1990). "NE-19550 and NE-21610, Antinociceptive Capsaicin Analogues: Studies on Nociceptive Fibres of the Neonatal Rat Tail in vitro," <i>Eur. J. Pharmacol.</i> 181:289-293.	
/M.Y./	61.	Dray, A. et al. (1991). "Systemic Capsaicin and Olvanil Reduce the Acute Alogogenic and the Late Inflammatory Phase Following Formalin Injection Into Rodent Paw," <i>Pain</i> 47:79-83.	
/M.Y./	62.	Durheim, H. et al. (July 1980). "Permeation of Hairless Mouse Skin I: Experimental Methods and Comparison with Human Epidermal Permeation by Alkanols," <i>J. Pharm. Sci.</i> 69(7):781-786.	
/M.Y./	63.	Ellis, C.N. et al. (1993). "A Double-Blind Evaluation of Topical Capsaicin in Pruritic Psoriasis," <i>J. Am Acad. Dermatol.</i> 29:438-442.	
/M.Y./	64.	Exintaris, B. et al. (July 2002). "Spontaneous Slow Wave and Contractile Activity of the Guinea Pig Prostate," <i>J. Urol.</i> 168:315-322.	
/M.Y./	65.	Fowler, C.J. et al. (2002). "Voiding and the Sacral Reflex Arc: Lessons from Capsaicin Instillation," <i>Scand. J. Urol. Nephro. Suppl.</i> 210:46-50.	
/M.Y./	66.	Franz, T.J. et al. (1992). "Transdermal Delivery" Chapter 8 In <u>Treatise on Controlled Drug Delivery</u> Kydonieus, A. ed. Marcel Dekker: New York, NY pp. 341-421.	
/M.Y./	67.	Franz, T.J. et al. (April 1990). "The Use of Water Permeability as a Means of Validation for Skin Integrity in in-vitro Percutaneous Absorption Studies," Abstract, <i>J. Invest. Dermatol.</i> 94(4):525.	
/M.Y./	68.	Friedrich, E.G. Jr. (June 1988). "Therapeutic Studies on Vulvar Vestibulitis," <i>Journal of Reprod. Med.</i> 33(6):514-518.	
	69.	Frot, M. et al. (2004). "Sex Differences in Pain Perception and Anxiety. A Psychophysical Study with Topical Capsaicin," <i>Pain</i> 108:230-236.	
	70.	Guyatt, G.H. et al. (1987). "A Comparison of Likert and Visual Analogue Scales for Measuring Change in Function," <i>J. Chronic Dis.</i> 40(12):1129-1133.	
	71.	Herrmann, D.N. et al. (March 2004). "Epidermal Nerve Fiber Density, Axonal Swellings and QST as Predictors of HIV Distal Sensory Neuropathy," <i>Muscle & Nerve</i> 29:420-427.	
	72.	Hoskin, P.J. et al. (1991). "Opioid Agonist-Antagonist Drugs in Acute and Chronic Pain States," <i>Drugs</i> 41(3):326-344.	
	73.	Hua, X.Y. et al. (1997). "Antinociception Induced by Civamide, an Orally Active Capsaicin Analogue," <i>Pain</i> 71:313-322.	
	74.	International Search Report for PCT Application No. PCT/US04/11336 filed on April 12, 2004, mailed on December 20, 2004, four pages.	
	75.	Jerman, J.C. et al. (June 2000). "Characterization Using FLIPR of Rat Vanilloid Receptor (vR1) Pharmacology," <i>Br. J. Pharmacol.</i> 130(4):916-922.	
	76.	Kaiko, R.F. (1986). "Controversy in the Management of Chronic Cancer Pain: Therapeutic Equivalents of IM and PO Morphine," <i>J. Pain Symptom Manage.</i> 1:42-45.	
	77.	Karande, P. et al. (February 2004). "Discovery of Transdermal Penetration Enhancers by High-Throughput Screening," <i>Nature Biotechnology</i> 22(2):192-197.	
	78.	Karande, P. et al. (May 2002). "High Throughput Screening of Transdermal Formulations," <i>Pharm. Res.</i> 19(5):655-660.	
	79.	Kasting, G.B. et al. (January 1997). "Percutaneous Absorption of Vanilloids: In Vivo and In Vitro Studies," <i>J. Pharm. Sci.</i> 86(1):142-146.	
	80.	Kemppainen, B.W. et al. eds. (1990). <u>Methods For Skin Absorption</u> CRC Press, Inc. (Table of Contents Only.)	
V	81.	Kennedy, W.R. et al. (1996). "Quantitation of Epidermal Nerves in Diabetic Neuropathy," <i>Neurology</i> 47:1042-1048.	
/M.Y./	82.	Kobayashi, Y. (May 2003). "The Nociceptive and Anti-Nociceptive Effects of Evodiamine from Fruits of <i>Evodia rutaecarpa</i> in Mice," <i>Planta Med</i> 69:425-428.	

Examiner Signature	/Micah Paul Young/ (02/17/2009)	Date Considered	02/17/2009
pa-982742			

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/823,426
		Filing Date	April 12, 2004
		First Named Inventor	Naweed MUHAMMAD
		Art Unit	1614
		Examiner Name	Not Yet Assigned
Sheet	4	of	5
		Attorney Docket Number	524522001300

/M.Y./	83.	Kobayashi, Y. et al. (2000). "The Bronchoconstrictive Action of Evodiamine, an Indoloquinazoline Alkaloid Isolated From the Fruits of <i>Evodia rutescarpa</i> , on Guinea-Pig Isolated Bronchus: Possible Involvement on Vanilloid Receptors," <i>Planta Med</i> 66:526-530.	
/M.Y./	84.	McArthur, J.C. et al. (December 1998), "Epidermal Nerve Fiber Density: Normative Reference Range and Diagnostic Efficiency," <i>Arch. Neurol.</i> 55:1513-1520.	
/M.Y./	85.	Moller, A.R. (2000). "Similarities Between Severe Tinnitus and Chronic Pain," <i>J. Am. Acad. Audiol.</i> 11:115-124.	
/M.Y./	86.	Montell, C. et al. (February 2002). "A Unified Nomenclature for the Superfamily of TRP Cation Channels," <i>Mol. Cell.</i> 9:229-231.	
/M.Y./	87.	Morré, D.J. et al. (June 15, 1997). "NADH Oxidase Activity from Sera Altered by Capsaicin is Widely Distributed Among Cancer Patients," <i>Arch. Biochem. Biophys.</i> 342(2):224-230.	
/M.Y./	88.	Nanji, A. A. et al. (1987). "Use of Skin Surface Sampling and Ion Mobility Spectrometry as a Preliminary Screening Method for Drug Detection in an Emergency Room," <i>Clin. Toxicol.</i> 25(6):501-515.	
/M.Y./	89.	Nolano, M. et al. (1999). "Topical Capsaicin in Humans: Parallel Loss of Epidermal Nerve Fibers and Pain Sensation," <i>J. Neuroscience</i> 81:135-145.	
/M.Y./	90.	Pershing, L.K. (2004). "Effects of Vehicle on the Uptake and Elimination Kinetics of Capsaicinoids in Human Skin In Vivo," <i>Toxicology and Applied Pharmacology</i> 200:73-81.	
/M.Y./	91.	Pertovaara, A. (1988). "Collateral Sprouting of Nociceptive C-Fibers After Cut or Capsaicin Treatment of the Sciatic Nerve in Adult Rats," <i>Neurosci. Lett.</i> 90:248-253.	
/M.Y./	92.	Prince, L.M. (March 4, 1970). "Microemulsions" <i>J. Soc. Cosmet. Chem.</i> 21:193-204.	
/M.Y./	93.	Prince, L.M. ed. (1977). "Schulman's Microemulsions" <i>In Microemulsions - Theory and Practice</i> Academic Press, Inc.: New York, NY pp. vii-viii (Table of Contents Only.)	
/M.Y./	94.	Saper, J.R. et al. (June 2002). "Intranasal Cividamide for the treatment of Episodic Cluster Headaches," <i>Arch. Neurol.</i> 59:990-994.	
/M.Y./	95.	Shifflet, M.J. et al. (2002). "Development of Analytical Methods to Accurately and Precisely Determine Residual Active Pharmaceutical Ingredients and Cleaning Agents on Pharmaceutical Surfaces," <i>American Pharmaceutical Review</i> pp. 35-40.	
/M.Y./	96.	Siao, P. et al. (2003). "Quantitative Sensory Testing," <i>Phys. Med. Rehabil. Clin. N. Am.</i> 14:261-286.	
	97.	Skofitsch, G. et al. (1984). "Comparison of Nonivamide and Capsaicin with Regard to their Pharmacokinetics and Effects on Sensory Neurons," <i>Arzneimittel Forschung</i> 34:154-156.	
	98.	Smart, D. et al. (2001). "Characterisation Using FLIPR of Human Vanilloid VR1 Receptor Pharmacology," <i>Eur. J. Pharmacol.</i> 417:51-58.	
	99.	Sternier, O. et al. (November 1999). "Novel Natural Vanilloid Receptor Agonists: New Therapeutic Targets for Drug Development," <i>Trends Pharmacol. Sci.</i> 20(11):459-465.	
	100.	Sullivan, E. et al. (1999). "Measurement of [Ca ²⁺] Using the Fluorometric Imaging Plate Reader (FLIPR)," Chapter 7 <i>In Methods in Molecular Biology</i> Lambert, D.G. ed. Humana Press, Inc.: Totowa, NJ 114:125-133.	
	101.	Surh, Y.-J. (2002). "Anti-Tumor Promoting Potential of Selected Spice Ingredients with Antioxidative and Anti-Inflammatory Activities: A Short Review," <i>Food Chem. Toxicol.</i> 40:1091-1097.	
	102.	Surh, Y.-J. (September 4, 2002). "More Than Spice: Capsaicin in Hot Chili Peppers Makes Tumor Cells Commit Suicide," <i>J. Nat. Cancer Inst.</i> 94(17):1263-1265.	
	103.	Szallasi, A. (2001). "Vanilloid Receptor Ligands: Hopes and Realities for the Future," <i>Drugs Aging</i> 18(8):561-573.	
	104.	Szallasi, A. et al. (1999). "Vanilloid (Capsaicin) Receptors and Mechanisms," <i>Pharm. Revs.</i> 51(2):159-211.	
	105.	Tayeb, M.T. et al. (2003). "CYP3A4 and VDR Gene Polymorphisms and the Risk of Prostate Cancer in Men with Benign Prostate Hyperplasia," <i>Br. J. Cancer</i> 88:928-932.	
/M.Y./	106.	Tojo, K. (1988). "Concentration Profile in Plasma After Transdermal Drug Delivery," <i>Int. J. Pharm.</i> 43:201-205.	

Examiner Signature	/Micah Paul Young/ (02/17/2009)	Date Considered	02/17/2009
pa-982742			

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/823,426
		Filing Date	April 12, 2004
		First Named Inventor	Naweed MUHAMMAD
		Art Unit	1614
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	524522001300
Sheet	5	of	5

/M.Y.	107.	Tojo, K. (June 1987). "Mathematical Modeling of Skin Permeation of Drugs," <i>J. Chem. Eng. Jpn.</i> 20(3):300-308.	
/M.Y.	108.	Townshend, A. ed. (1995). "Turbidimetry and Nephelometry" <i>In Encyclopedia of Analytical Science</i> Academic Press Ltd., UK (Table of Contents Only.)	
/M.Y.	109.	Tsai, Y-H. et al. (1994). "Percutaneous Absorption of Capsaicin and its Derivatives," <i>Drug Devel. Industrial Pharm.</i> 20(4):719-730.	
/M.Y.	110.	Tympanidis, P. et al. (2004). "Increased Vanilloid Receptor VR1 Innervation In Vulvodynia," <i>European Journal of Pain</i> 8:129-133.	
/M.Y.	111.	Van der Aa, F. et al. (2003). "Interstitial Cells in the Human Prostate: A New Therapeutic Target?" <i>Prostate</i> 56:250-255.	
/M.Y.	112.	Vass, Z. et al. (2001). "Capsaicin Stimulation of the Cochlea and Electric Stimulation of the Trigeminal Ganglion Mediate Vascular Permeability in Cochlear and Vertebral-Basilar Arteries: A Potential Cause of Inner Ear Dysfunction in Headache," <i>Neuroscience</i> 103(1):189-201.	
/M.Y.	113.	Venter, J.P. et al. (2001). "A Comparative Study of an in situ Adapted Diffusion Cell and an in vitro Franz Diffusion Cell Method for Transdermal Absorption of Doxylamine," <i>Eur. J. Pharm. Sci.</i> 13:169-177.	
/M.Y.	114.	Wang, Y-Y. et al. (2001). "In vitro and in vivo Evaluations of Topically Applied Capsaicin and Nonivamide From Hydrogels," <i>Int. J. Pharm.</i> 224:89-104.	
/M.Y.	115.	Witte, D.G. et al. (2002). "Use of a Fluorescent Imaging Plate Reader-Based Calcium Assay to Assess Pharmacological Differences Between the Human and Rat Vanilloid Receptor," <i>J. Biomol. Screen</i> 7(5):466-475.	
/M.Y.	116.	Zahner, M.R. et al. (2003). "Cardiac Vanilloid Receptor 1-Expressing Afferent Nerves and Their Role in the Cardiogenic Sympathetic Reflex in Rats," <i>J. Physiol.</i> 551(2):515-523.	
/M.Y.	117.	Zatz, J.L. (1993). "Scratching the Surface: Rationale and Approaches to Skin Permeation" Chapter 1 <i>In Skin Permeation, Fundamentals and Application</i> Zatz, J.L. ed. Allured Publishing Corp.: Wheaton, IL pp. 11-31.	
/M.Y.	118.	Zheng, J. et al. (March 26, 2003). "Vanilloid Receptors in Hearing: Altered Cochlear Sensitivity by Vanilloids and Expression of TRPV1 in the Organ of Corti," <i>J. Neurophysiol.</i> 90:444-455.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Micah Paul Young/ (02/17/2009)	Date Considered	02/17/2009
pa-982742			